Header Logo

Anne-Marie Malfait

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentInternal Medicine, Division of Rheumatology
Address1611 W. Harrison St.
Chicago IL 60612
Phone312-942-2925
Fax312) 942-3073
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My ORCID is 0000-0003-1428-0384.
    My Scopus ID is 7003614501.
    My NIH COMMONS name is AMMALFAIT.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. George DS, Jayaraj ND, Pacifico P, Ren D, Sriram N, Miller RE, Malfait AM, Miller RJ, Menichella DM. The Mas-related G protein-coupled receptor d (Mrgprd) mediates pain hypersensitivity in painful diabetic neuropathy. Pain. 2023 Dec 22. PMID: 38147415.
      Citations:    
    2. Obeidat AM, Kim SY, Burt KG, Hu B, Li J, Ishihara S, Xiao R, Miller RE, Little C, Malfait AM, Scanzello CR. Recommendations For a Standardized Approach to Histopathologic Evaluation of Synovial Membrane in Murine Models of Experimental Osteoarthritis. bioRxiv. 2023 Oct 18. PMID: 37904981.
      Citations:    
    3. Bergman RF, Lammlin L, Junginger L, Farrell E, Goldman S, Darcy R, Rasner C, Obeidat AM, Malfait AM, Miller RE, Maerz T. Sexual dimorphism of the synovial transcriptome underpins greater PTOA disease severity in male mice following joint injury. Osteoarthritis Cartilage. 2023 Sep 15. PMID: 37716404.
      Citations:    
    4. Bai Z, Bartelo N, Aslam M, Hale C, Blachere NE, Parveen S, Spolaore E, DiCarlo E, Gravallese E, Smith MH, Frank MO, Jiang CS, Zhang H, Lewis MJ, Sikandar S, Pitzalis C, Malfait AM, Miller RE, Zhang F, Goodman S, Darnell R, Wang F, Orange DE. Machine Learning Reveals Synovial Fibroblast Genes Associated with Pain Affect Sensory Nerve Growth in Rheumatoid Arthritis. medRxiv. 2023 Aug 23. PMID: 37662384.
      Citations:    
    5. Vroman R, Hunter RS, Wood MJ, Davis OC, Malfait Z, George DS, Ren D, Tavares-Ferreira D, Price TJ, Miller RJ, Malfait AM, Malfait F, Miller RE, Syx D. Analysis of matrisome expression patterns in murine and human dorsal root ganglia. Front Mol Neurosci. 2023; 16:1232447. PMID: 37664243.
      Citations:    
    6. Geraghty T, Obeidat AM, Ishihara S, Wood MJ, Li J, Lopes EBP, Scanzello CR, Griffin TM, Malfait AM, Miller RE. Age-Associated Changes in Knee Osteoarthritis, Pain-Related Behaviors, and Dorsal Root Ganglia Immunophenotyping of Male and Female Mice. Arthritis Rheumatol. 2023 10; 75(10):1770-1780. PMID: 37096632.
      Citations:    
    7. Colman M, Syx D, De Wandele I, Rombaut L, Wille D, Malfait Z, Meeus M, Malfait AM, Van Oosterwijck J, Malfait F. Sensory Profiling in Classical Ehlers-Danlos Syndrome: A Case-Control Study Revealing Pain Characteristics, Somatosensory Changes, and Impaired Pain Modulation. J Pain. 2023 11; 24(11):2063-2078. PMID: 37380025.
      Citations:    
    8. Obeidat AM, Wood MJ, Adamczyk NS, Ishihara S, Li J, Wang L, Ren D, Bennett DA, Miller RJ, Malfait AM, Miller RE. Piezo2 expressing nociceptors mediate mechanical sensitization in experimental osteoarthritis. Nat Commun. 2023 04 29; 14(1):2479. PMID: 37120427.
      Citations:    
    9. Wang L, Ishihara S, Li J, Miller RE, Malfait AM. Notch signaling is activated in knee-innervating dorsal root ganglia in experimental models of osteoarthritis joint pain. Arthritis Res Ther. 2023 04 15; 25(1):63. PMID: 37061736.
      Citations:    
    10. Colman M, Syx D, de Wandele I, Rombaut L, Wilie D, Malfait Z, Meeus M, Malfait AM, Van Oosterwijck J, Malfait F. Sensory profiling in classical Ehlers-Danlos syndrome: a case-control study revealing pain characteristics, somatosensory changes, and impaired pain modulation. medRxiv. 2023 Feb 26. PMID: 36865307.
      Citations:    
    11. Hunter DJ, Malfait AM. Doubling down on osteoarthritis: statement from the incoming editors-in-chief. Osteoarthritis Cartilage. 2022 08; 30(8):1013-1014. PMID: 35691475.
      Citations:    
    12. Wood MJ, Miller RE, Malfait AM. The Genesis of Pain in Osteoarthritis: Inflammation as a Mediator of Osteoarthritis Pain. Clin Geriatr Med. 2022 05; 38(2):221-238. PMID: 35410677.
      Citations:    
    13. George DS, Hackelberg S, Jayaraj ND, Ren D, Edassery SL, Rathwell CA, Miller RE, Malfait AM, Savas JN, Miller RJ, Menichella DM. Mitochondrial calcium uniporter deletion prevents painful diabetic neuropathy by restoring mitochondrial morphology and dynamics. Pain. 2022 03 01; 163(3):560-578. PMID: 34232927.
      Citations:    
    14. Malfait F, Colman M, Vroman R, De Wandele I, Rombaut L, Miller RE, Malfait AM, Syx D. Pain in the Ehlers-Danlos syndromes: Mechanisms, models, and challenges. Am J Med Genet C Semin Med Genet. 2021 12; 187(4):429-445. PMID: 34797601.
      Citations:    
    15. Vroman R, Malfait AM, Miller RE, Malfait F, Syx D. Animal Models of Ehlers-Danlos Syndromes: Phenotype, Pathogenesis, and Translational Potential. Front Genet. 2021; 12:726474. PMID: 34712265.
      Citations:    
    16. Miller RE, Malfait AM. Can we prevent chronic osteoarthritis pain? A view from the bench. Osteoarthritis Cartilage. 2021 12; 29(12):1635-1637. PMID: 34628019.
      Citations:    
    17. Malfait AM, Miller RE, Miller RJ. Basic Mechanisms of Pain in Osteoarthritis: Experimental Observations and New Perspectives. Rheum Dis Clin North Am. 2021 05; 47(2):165-180. PMID: 33781488.
      Citations:    
    18. Ishihara S, Obeidat AM, Wokosin DL, Ren D, Miller RJ, Malfait AM, Miller RE. The role of intra-articular neuronal CCR2 receptors in knee joint pain associated with experimental osteoarthritis in mice. Arthritis Res Ther. 2021 04 07; 23(1):103. PMID: 33827672.
      Citations:    
    19. Geraghty T, Winter DR, Miller RJ, Miller RE, Malfait AM. Neuroimmune interactions and osteoarthritis pain: focus on macrophages. Pain Rep. 2021; 6(1):e892. PMID: 33981927.
      Citations:    
    20. Syx D, Miller RE, Obeidat AM, Tran PB, Vroman R, Malfait Z, Miller RJ, Malfait F, Malfait AM. Pain-related behaviors and abnormal cutaneous innervation in a murine model of classical Ehlers-Danlos syndrome. Pain. 2020 10; 161(10):2274-2283. PMID: 32483055.
      Citations:    
    21. Malfait AM, Miller RE, Block JA. Targeting neurotrophic factors: Novel approaches to musculoskeletal pain. Pharmacol Ther. 2020 07; 211:107553. PMID: 32311372.
      Citations:    
    22. Miller RE, Tran PB, Ishihara S, Syx D, Ren D, Miller RJ, Valdes AM, Malfait AM. Microarray analyses of the dorsal root ganglia support a role for innate neuro-immune pathways in persistent pain in experimental osteoarthritis. Osteoarthritis Cartilage. 2020 05; 28(5):581-592. PMID: 31982564.
      Citations:    
    23. Malfait AM, Miller RE. Why we should study osteoarthritis pain in experimental models in both sexes. Osteoarthritis Cartilage. 2020 04; 28(4):397-399. PMID: 31926266.
      Citations:    
    24. Miller RJ, Malfait AM, Miller RE. The innate immune response as a mediator of osteoarthritis pain. Osteoarthritis Cartilage. 2020 05; 28(5):562-571. PMID: 31862470.
      Citations:    
    25. Malfait AM, Tortorella MD. The "elusive DMOAD": Aggrecanase inhibition from laboratory to clinic. Clin Exp Rheumatol. 2019 Sep-Oct; 37 Suppl 120(5):130-134. PMID: 31621572.
      Citations:    
    26. Miller RE, Scanzello CR, Malfait AM. An emerging role for Toll-like receptors at the neuroimmune interface in osteoarthritis. Semin Immunopathol. 2019 09; 41(5):583-594. PMID: 31612243.
      Citations:    
    27. Malfait AM, Pincus T. New concepts in osteoarthritis. Clin Exp Rheumatol. 2019 Sep-Oct; 37 Suppl 120(5):2. PMID: 31621567.
      Citations:    
    28. Schmelz M, Mantyh P, Malfait AM, Farrar J, Yaksh T, Tive L, Viktrup L. Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety. Pain. 2019 10; 160(10):2210-2220. PMID: 31145219.
      Citations:    
    29. Obeidat AM, Miller RE, Miller RJ, Malfait AM. The nociceptive innervation of the normal and osteoarthritic mouse knee. Osteoarthritis Cartilage. 2019 11; 27(11):1669-1679. PMID: 31351964.
      Citations:    
    30. Chua JR, Jamal S, Riad M, Castrejon I, Malfait AM, Block JA, Pincus T. Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later. Arthritis Rheumatol. 2019 08; 71(8):1276-1284. PMID: 30891933.
      Citations:    
    31. Miller RE, Block JA, Malfait AM. What is new in pain modification in osteoarthritis? Rheumatology (Oxford). 2018 05 01; 57(suppl_4):iv99-iv107. PMID: 29361112.
      Citations:    
    32. Miller RE, Malfait AM. Osteoarthritis pain: What are we learning from animal models? Best Pract Res Clin Rheumatol. 2017 10; 31(5):676-687. PMID: 30509413.
      Citations:    
    33. Miller RE, Ishihara S, Tran PB, Golub SB, Last K, Miller RJ, Fosang AJ, Malfait AM. An aggrecan fragment drives osteoarthritis pain through Toll-like receptor 2. JCI Insight. 2018 03 22; 3(6). PMID: 29563338.
      Citations:    
    34. Syx D, Tran PB, Miller RE, Malfait AM. Peripheral Mechanisms Contributing to Osteoarthritis Pain. Curr Rheumatol Rep. 2018 02 26; 20(2):9. PMID: 29480410.
      Citations:    
    35. Miller RE, Kim YS, Tran PB, Ishihara S, Dong X, Miller RJ, Malfait AM. Visualization of Peripheral Neuron Sensitization in a Surgical Mouse Model of Osteoarthritis by In Vivo Calcium Imaging. Arthritis Rheumatol. 2018 01; 70(1):88-97. PMID: 28992367.
      Citations:    
    36. Malfait AM. Why we should study pain in animal models of rheumatic diseases. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):37-39. PMID: 28967366.
      Citations:    
    37. Miller RE, Malfait AM, Block JA. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):85-87. PMID: 28967370.
      Citations:    
    38. Malfait AM, Pincus T. Pain in rheumatic diseases. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 107(5):1. PMID: 28967375.
      Citations:    
    39. Sambamurthy N, Nguyen V, Smalley R, Xiao R, Hankenson K, Gan J, Miller RE, Malfait AM, Dodge GR, Scanzello CR. Chemokine receptor-7 (CCR7) deficiency leads to delayed development of joint damage and functional deficits in a murine model of osteoarthritis. J Orthop Res. 2018 03; 36(3):864-875. PMID: 28767178.
      Citations:    
    40. Miller RE, Ishihara S, Bhattacharyya B, Delaney A, Menichella DM, Miller RJ, Malfait AM. Chemogenetic Inhibition of Pain Neurons in a Mouse Model of Osteoarthritis. Arthritis Rheumatol. 2017 07; 69(7):1429-1439. PMID: 28380690.
      Citations:    
    41. Vincent T, Malfait AM. Time to be positive about negative data? Osteoarthritis Cartilage. 2017 03; 25(3):351-353. PMID: 28224967.
      Citations:    
    42. Miller RE, Malfait AM. Can we target CCR2 to treat osteoarthritis? The trick is in the timing! Osteoarthritis Cartilage. 2017 06; 25(6):799-801. PMID: 28189827.
      Citations:    
    43. Miller RE, Block JA, Malfait AM. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? Curr Opin Rheumatol. 2017 01; 29(1):110-118. PMID: 27672741.
      Citations:    
    44. Trevino RL, Pacione CA, Malfait AM, Chubinskaya S, Wimmer MA. Development of a Cartilage Shear-Damage Model to Investigate the Impact of Surface Injury on Chondrocytes and Extracellular Matrix Wear. Cartilage. 2017 Oct; 8(4):444-455. PMID: 28934882.
      Citations:    
    45. Malfait AM, Miller RJ. Emerging Targets for the Management of Osteoarthritis Pain. Curr Osteoporos Rep. 2016 12; 14(6):260-268. PMID: 27730452.
      Citations:    
    46. Miotla Zarebska J, Chanalaris A, Driscoll C, Burleigh A, Miller RE, Malfait AM, Stott B, Vincent TL. CCL2 and CCR2 regulate pain-related behaviour and early gene expression in post-traumatic murine osteoarthritis but contribute little to chondropathy. Osteoarthritis Cartilage. 2017 03; 25(3):406-412. PMID: 27746376.
      Citations:    
    47. Tran PB, Miller RE, Ishihara S, Miller RJ, Malfait AM. Spinal microglial activation in a murine surgical model of knee osteoarthritis. Osteoarthritis Cartilage. 2017 05; 25(5):718-726. PMID: 27646532.
      Citations:    
    48. Malfait AM. Osteoarthritis year in review 2015: biology. Osteoarthritis Cartilage. 2016 Jan; 24(1):21-6. PMID: 26707989.
      Citations:    
    49. Miller RE, Belmadani A, Ishihara S, Tran PB, Ren D, Miller RJ, Malfait AM. Damage-associated molecular patterns generated in osteoarthritis directly excite murine nociceptive neurons through Toll-like receptor 4. Arthritis Rheumatol. 2015 Nov; 67(11):2933-43. PMID: 26245312.
      Citations:    
    50. Miller RE, Tran PB, Obeidat AM, Raghu P, Ishihara S, Miller RJ, Malfait AM. The Role of Peripheral Nociceptive Neurons in the Pathophysiology of Osteoarthritis Pain. Curr Osteoporos Rep. 2015 Oct; 13(5):318-26. PMID: 26233284.
      Citations:    
    51. Miller RE, Tran PB, Ishihara S, Larkin J, Malfait AM. Therapeutic effects of an anti-ADAMTS-5 antibody on joint damage and mechanical allodynia in a murine model of osteoarthritis. Osteoarthritis Cartilage. 2016 Feb; 24(2):299-306. PMID: 26410555.
      Citations:    
    52. Malfait AM, Little CB. On the predictive utility of animal models of osteoarthritis. Arthritis Res Ther. 2015 Sep 14; 17:225. PMID: 26364707.
      Citations:    
    53. Chen S, Cao P, Dong N, Peng J, Zhang C, Wang H, Zhou T, Yang J, Zhang Y, Martelli EE, Naga Prasad SV, Miller RE, Malfait AM, Zhou Y, Wu Q. PCSK6-mediated corin activation is essential for normal blood pressure. Nat Med. 2015 Sep; 21(9):1048-53. PMID: 26259032.
      Citations:    
    54. Larkin J, Lohr TA, Elefante L, Shearin J, Matico R, Su JL, Xue Y, Liu F, Genell C, Miller RE, Tran PB, Malfait AM, Maier CC, Matheny CJ. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 2015 Aug; 23(8):1254-66. PMID: 25800415.
      Citations:    
    55. Miller RE, Miller RJ, Malfait AM. Osteoarthritis joint pain: the cytokine connection. Cytokine. 2014 Dec; 70(2):185-93. PMID: 25066335.
      Citations:    
    56. Malfait AM, Schnitzer TJ. Towards a mechanism-based approach to pain management in osteoarthritis. Nat Rev Rheumatol. 2013 Nov; 9(11):654-64. PMID: 24045707.
      Citations:    
    57. Malfait AM, Little CB, McDougall JJ. A commentary on modelling osteoarthritis pain in small animals. Osteoarthritis Cartilage. 2013 Sep; 21(9):1316-26. PMID: 23973146.
      Citations:    
    58. Miller RE, Lu Y, Tortorella MD, Malfait AM. Genetically Engineered Mouse Models Reveal the Importance of Proteases as Osteoarthritis Drug Targets. Curr Rheumatol Rep. 2013 Aug; 15(8):350. PMID: 23926636.
      Citations:    
    59. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, Malfait AM. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A. 2012 Dec 11; 109(50):20602-7. PMID: 23185004.
      Citations:    
    60. Morgen M, Tung D, Boras B, Miller W, Malfait AM, Tortorella M. Nanoparticles for improved local retention after intra-articular injection into the knee joint. Pharm Res. 2013 Jan; 30(1):257-68. PMID: 22996566.
      Citations:    
    61. Nair A, Kanda V, Bush-Joseph C, Verma N, Chubinskaya S, Mikecz K, Glant TT, Malfait AM, Crow MK, Spear GT, Finnegan A, Scanzello CR. Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to toll-like receptor 4 and toll-like receptor 2 ligands via soluble CD14. Arthritis Rheum. 2012 Jul; 64(7):2268-77. PMID: 22492243.
      Citations:    
    62. Malfait AM, Seymour AB, Gao F, Tortorella MD, Le Graverand-Gastineau MP, Wood LS, Doherty M, Doherty S, Zhang W, Arden NK, Vaughn FL, Leaverton PE, Spector TD, Hart DJ, Maciewicz RA, Muir KR, Das R, Sorge RE, Sotocinal SG, Schorscher-Petcu A, Valdes AM, Mogil JS. A role for PACE4 in osteoarthritis pain: evidence from human genetic association and null mutant phenotype. Ann Rheum Dis. 2012 Jun; 71(6):1042-8. PMID: 22440827.
      Citations:    
    63. Malfait AM. Modelling pain in post-traumatic osteoarthritis of the knee. Pain. 2012 Feb; 153(2):257-258. PMID: 22018974.
      Citations:    
    64. Shieh HS, Tomasselli AG, Mathis KJ, Schnute ME, Woodard SS, Caspers N, Williams JM, Kiefer JR, Munie G, Wittwer A, Malfait AM, Tortorella MD. Structure analysis reveals the flexibility of the ADAMTS-5 active site. Protein Sci. 2011 Apr; 20(4):735-44. PMID: 21370305.
      Citations:    
    65. Li J, Anemaet W, Diaz MA, Buchanan S, Tortorella M, Malfait AM, Mikecz K, Sandy JD, Plaas A. Knockout of ADAMTS5 does not eliminate cartilage aggrecanase activity but abrogates joint fibrosis and promotes cartilage aggrecan deposition in murine osteoarthritis models. J Orthop Res. 2011 Apr; 29(4):516-22. PMID: 21337391.
      Citations:    
    66. Dufield DR, Nemirovskiy OV, Jennings MG, Tortorella MD, Malfait AM, Mathews WR. An immunoaffinity liquid chromatography-tandem mass spectrometry assay for detection of endogenous aggrecan fragments in biological fluids: Use as a biomarker for aggrecanase activity and cartilage degradation. Anal Biochem. 2010 Nov 15; 406(2):113-23. PMID: 20603097.
      Citations:    
    67. Byun S, Tortorella MD, Malfait AM, Fok K, Frank EH, Grodzinsky AJ. Transport and equilibrium uptake of a peptide inhibitor of PACE4 into articular cartilage is dominated by electrostatic interactions. Arch Biochem Biophys. 2010 Jul; 499(1-2):32-9. PMID: 20447377.
      Citations:    
    68. Malfait AM, Ritchie J, Gil AS, Austin JS, Hartke J, Qin W, Tortorella MD, Mogil JS. ADAMTS-5 deficient mice do not develop mechanical allodynia associated with osteoarthritis following medial meniscal destabilization. Osteoarthritis Cartilage. 2010 Apr; 18(4):572-80. PMID: 20036347.
      Citations:    
    69. Zack MD, Malfait AM, Skepner AP, Yates MP, Griggs DW, Hall T, Hills RL, Alston JT, Nemirovskiy OV, Radabaugh MR, Leone JW, Arner EC, Tortorella MD. ADAM-8 isolated from human osteoarthritic chondrocytes cleaves fibronectin at Ala(271). Arthritis Rheum. 2009 Sep; 60(9):2704-13. PMID: 19714641.
      Citations:    
    70. Zack MD, Melton MA, Stock JL, Storer CE, Barve RA, Minnerly JC, Weiss DJ, Stejskal JA, Tortorella MD, Turk JR, Shevlin KM, Malfait AM. Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8). Clin Exp Immunol. 2009 Nov; 158(2):246-56. PMID: 19737139.
      Citations:    
    71. Tortorella MD, Tomasselli AG, Mathis KJ, Schnute ME, Woodard SS, Munie G, Williams JM, Caspers N, Wittwer AJ, Malfait AM, Shieh HS. Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors. J Biol Chem. 2009 Sep 04; 284(36):24185-91. PMID: 19586907.
      Citations:    
    72. Tortorella MD, Malfait F, Barve RA, Shieh HS, Malfait AM. A review of the ADAMTS family, pharmaceutical targets of the future. Curr Pharm Des. 2009; 15(20):2359-74. PMID: 19601837.
      Citations:    
    73. Malfait AM, Tortorella M, Thompson J, Hills R, Meyer DM, Jaffee BD, Chinn K, Ghoreishi-Haack N, Markosyan S, Arner EC. Intra-articular injection of tumor necrosis factor-alpha in the rat: an acute and reversible in vivo model of cartilage proteoglycan degradation. Osteoarthritis Cartilage. 2009 May; 17(5):627-35. PMID: 19026578.
      Citations:    
    74. Malfait AM, Arner EC, Song RH, Alston JT, Markosyan S, Staten N, Yang Z, Griggs DW, Tortorella MD. Proprotein convertase activation of aggrecanases in cartilage in situ. Arch Biochem Biophys. 2008 Oct 01; 478(1):43-51. PMID: 18671934.
      Citations:    
    75. Tortorella MD, Malfait AM. Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis. Curr Pharm Biotechnol. 2008 Feb; 9(1):16-23. PMID: 18289053.
      Citations:    
    76. Shieh HS, Mathis KJ, Williams JM, Hills RL, Wiese JF, Benson TE, Kiefer JR, Marino MH, Carroll JN, Leone JW, Malfait AM, Arner EC, Tortorella MD, Tomasselli A. High resolution crystal structure of the catalytic domain of ADAMTS-5 (aggrecanase-2). J Biol Chem. 2008 Jan 18; 283(3):1501-1507. PMID: 17991750.
      Citations:    
    77. Blair WS, Cao J, Jackson L, Jimenez J, Peng Q, Wu H, Isaacson J, Butler SL, Chu A, Graham J, Malfait AM, Tortorella M, Patick AK. Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing. Antimicrob Agents Chemother. 2007 Oct; 51(10):3554-61. PMID: 17646410.
      Citations:    
    78. Wittwer AJ, Hills RL, Keith RH, Munie GE, Arner EC, Anglin CP, Malfait AM, Tortorella MD. Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (Aggrecanase 1). Biochemistry. 2007 May 29; 46(21):6393-401. PMID: 17487981.
      Citations:    
    79. Hall T, Fok KF, Liu MM, Zobel JF, Marino MH, Malfait AM, Tortorella MD, Tomasselli AG. A high performance liquid chromatography assay for monitoring proprotein convertase activity. J Chromatogr A. 2007 Apr 27; 1148(1):46-54. PMID: 17391681.
      Citations:    
    80. Hills R, Mazzarella R, Fok K, Liu M, Nemirovskiy O, Leone J, Zack MD, Arner EC, Viswanathan M, Abujoub A, Muruganandam A, Sexton DJ, Bassill GJ, Sato AK, Malfait AM, Tortorella MD. Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate. J Biol Chem. 2007 Apr 13; 282(15):11101-9. PMID: 17311924.
      Citations:    
    81. Song RH, Tortorella MD, Malfait AM, Alston JT, Yang Z, Arner EC, Griggs DW. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum. 2007 Feb; 56(2):575-85. PMID: 17265492.
      Citations:    
    82. Zack MD, Arner EC, Anglin CP, Alston JT, Malfait AM, Tortorella MD. Identification of fibronectin neoepitopes present in human osteoarthritic cartilage. Arthritis Rheum. 2006 Sep; 54(9):2912-22. PMID: 16948117.
      Citations:    
    83. Tortorella MD, Arner EC, Hills R, Gormley J, Fok K, Pegg L, Munie G, Malfait AM. ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms. Arch Biochem Biophys. 2005 Dec 01; 444(1):34-44. PMID: 16289022.
      Citations:    
    84. Sumariwalla PF, Malfait AM, Feldmann M. P-selectin glycoprotein ligand 1 therapy ameliorates established collagen-induced arthritis in DBA/1 mice partly through the suppression of tumour necrosis factor. Clin Exp Immunol. 2004 Apr; 136(1):67-75. PMID: 15030516.
      Citations:    
    85. Wang P, Tortorella M, England K, Malfait AM, Thomas G, Arner EC, Pei D. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. J Biol Chem. 2004 Apr 09; 279(15):15434-40. PMID: 14744861.
      Citations:    
    86. Tortorella MD, Arner EC, Hills R, Easton A, Korte-Sarfaty J, Fok K, Wittwer AJ, Liu RQ, Malfait AM. Alpha2-macroglobulin is a novel substrate for ADAMTS-4 and ADAMTS-5 and represents an endogenous inhibitor of these enzymes. J Biol Chem. 2004 Apr 23; 279(17):17554-61. PMID: 14715656.
      Citations:    
    87. Tortorella MD, Malfait AM. The usual suspects: verdict not guilty? Arthritis Rheum. 2003 Dec; 48(12):3304-7. PMID: 14673981.
      Citations:    
    88. Malfait AM, Liu RQ, Ijiri K, Komiya S, Tortorella MD. Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem. 2002 Jun 21; 277(25):22201-8. PMID: 11956193.
      Citations:    
    89. Tortorella MD, Malfait AM, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage. 2001 Aug; 9(6):539-52. PMID: 11520168.
      Citations:    
    90. Malfait AM, Williams RO, Malik AS, Maini RN, Feldmann M. Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arthritis Rheum. 2001 May; 44(5):1215-24. PMID: 11352257.
      Citations:    
    91. Feldmann M, Miotla J, Paleolog E, Williams R, Malfait AM, Taylor P, Brennan FM, Maini RN. Future prospects for anti-cytokine treatment. Ann Rheum Dis. 2000 Nov; 59 Suppl 1:i119-22. PMID: 11053102.
      Citations:    
    92. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000 Aug 15; 97(17):9561-6. PMID: 10920191.
      Citations:    
    93. Williams RO, Malfait AM, Butler DM, Walmsley MJ, Feldmann M, Maini RN. Combination therapy with DMARDs and biological agents in collagen-induced arthritis. Clin Exp Rheumatol. 1999 Nov-Dec; 17(6 Suppl 18):S115-20. PMID: 10589369.
      Citations:    
    94. Butler DM, Malfait AM, Maini RN, Brennan FM, Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol. 1999 07; 29(7):2205-12. PMID: 10427983.
      Citations:    
    95. Malfait AM, Malik AS, Marinova-Mutafchieva L, Butler DM, Maini RN, Feldmann M. The beta2-adrenergic agonist salbutamol is a potent suppressor of established collagen-induced arthritis: mechanisms of action. J Immunol. 1999 May 15; 162(10):6278-83. PMID: 10229875.
      Citations:    
    96. Malfait AM, Butler DM, Presky DH, Maini RN, Brennan FM, Feldmann M. Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol. 1998 Feb; 111(2):377-83. PMID: 9486407.
      Citations:    
    97. Ross SE, Williams RO, Mason LJ, Mauri C, Marinova-Mutafchieva L, Malfait AM, Maini RN, Feldmann M. Suppression of TNF-alpha expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol. 1997 Dec 15; 159(12):6253-9. PMID: 9550429.
      Citations:    
    98. Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, Feldmann M, Brennan FM. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol. 1997 Sep 15; 159(6):2867-76. PMID: 9300710.
      Citations:    
    99. Verbruggen G, Malfait AM, Dewulf M, Broddelez C, Veys EM. Standardization of nutrient media for isolated human articular chondrocytes in gelified agarose suspension culture. Osteoarthritis Cartilage. 1995 Dec; 3(4):249-59. PMID: 8689460.
      Citations:    
    100. De Geeter F, Malfait AM, Van Hoof A. Aspergilloma of the thoracic wall. Another cold spot lesion on bone scanning. Clin Nucl Med. 1995 May; 20(5):462. PMID: 7628158.
      Citations:    
    101. Malfait AM, Verbruggen G, Almqvist KF, Broddelez C, Veys EM. Coculture of human articular chondrocytes with peripheral blood mononuclear cells as a model to study cytokine-mediated interactions between inflammatory cells and target cells in the rheumatoid joint. In Vitro Cell Dev Biol Anim. 1994 Nov; 30A(11):747-52. PMID: 7881628.
      Citations:    
    102. Malfait AM, Verbruggen G, Veys EM, Lambert J, De Ridder L, Cornelissen M. Comparative and combined effects of interleukin 6, interleukin 1 beta, and tumor necrosis factor alpha on proteoglycan metabolism of human articular chondrocytes cultured in agarose. J Rheumatol. 1994 Feb; 21(2):314-20. PMID: 8182643.
      Citations:    
    103. Mielants H, Veys EM, De Keyser F, Ghyselen G, Malfait AM. Second conference on spondylarthropathies and the gut. Clin Exp Rheumatol. 1994 Jan-Feb; 12(1):111-6. PMID: 8162636.
      Citations:    
    104. De Keyser F, Verbruggen G, Veys EM, Cuvelier C, Malfait AM, Benoit D, Elewaut D, Vermeersch J, Heirwegh A. T cell receptor V beta usage in rheumatoid nodules: marked oligoclonality among IL-2 expanded lymphocytes. Clin Immunol Immunopathol. 1993 Jul; 68(1):29-34. PMID: 8513590.
      Citations:    
    105. Verbruggen G, Malfait AM, Veys EM, Gyselbrecht L, Lambert J, Almqvist KF. Influence of interferon-gamma on isolated chondrocytes from human articular cartilage. Dose dependent inhibition of cell proliferation and proteoglycan synthesis. J Rheumatol. 1993 Jun; 20(6):1020-6. PMID: 8350308.
      Citations:    
    106. Cornelissen M, Dewulf M, Verbruggen G, Hellebuyck P, Malfait AM, De Ridder L, Veys EM. Size distribution of native aggrecan aggregates of human articular chondrocytes in agarose. In Vitro Cell Dev Biol Anim. 1993 May; 29A(5):356-8. PMID: 8314729.
      Citations:    
    107. Verbruggen G, Malfait AM, Almqvist KF, Veys EM, Thenet S, Benoit B, Demignot S, Tachet des Combes A, Adolphe M. Development of immortalized human articular cartilage cell lines. Agents Actions Suppl. 1993; 39:267-72. PMID: 8456640.
      Citations:    
    108. De Keyser F, Benoit D, Elewaut D, Leroy B, Malfait AM, Verbruggen G, Veys EM. T-cell receptor expression in patients with rheumatic diseases. Prog Histochem Cytochem. 1992; 26(1-4):218-22. PMID: 1484963.
      Citations:    
    109. Verbruggen G, Veys EM, Malfait AM, De Clercq L, Van den Bosch F, de Vlam K. Influence of human recombinant interleukin-1 beta on human articular cartilage. Mitotic activity and proteoglycan metabolism. Clin Exp Rheumatol. 1991 Sep-Oct; 9(5):481-8. PMID: 1954699.
      Citations:    
    110. Verbruggen G, Veys EM, Wieme N, Malfait AM, Gijselbrecht L, Nimmegeers J, Almquist KF, Broddelez C. The synthesis and immobilisation of cartilage-specific proteoglycan by human chondrocytes in different concentrations of agarose. Clin Exp Rheumatol. 1990 Jul-Aug; 8(4):371-8. PMID: 2204512.
      Citations:    
    111. Verbruggen G, Veys EM, Malfait AM, Schatteman L, Wieme N, Nimmegeers J, Gerin MG, Broddelez C. Proteoglycan metabolism in isolated chondrocytes from human cartilage. Influence of niflumic acid. Clin Rheumatol. 1990 Mar; 9(1):32-41. PMID: 2335050.
      Citations:    
    112. Verbruggen G, Veys EM, Malfait AM, Schatteman L, Wieme N, Nimmegeers J, Gerin MG, Broddelez C. Proteoglycan metabolism in tissue-cultured human articular cartilage. Influence of niflumic acid. Scand J Rheumatol. 1990; 19(4):257-68. PMID: 2402599.
      Citations:    
    113. Verbruggen G, Veys EM, Malfait AM, Cochez P, Schatteman L, Wieme N, Heynen G, Broddelez C. Proteoglycan metabolism in tissue cultured human articular cartilage. Influence of piroxicam. J Rheumatol. 1989 Mar; 16(3):355-62. PMID: 2724253.
      Citations:    
    114. Verbruggen G, Veys EM, Malfait AM, Schatteman L, Wieme N, Heynen G, Vanhoutte V, Broddelez C. Proteoglycan metabolism in isolated chondrocytes from human cartilage and in short-term tissue-cultured human articular cartilage. Clin Exp Rheumatol. 1989 Jan-Feb; 7(1):13-7. PMID: 2706816.
      Citations:    
    Malfait's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (423)
    Explore
    _
    Co-Authors (13)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _